APL.BO · BSE
ASSTON PHARMACEUTICALS LIMITED
₹97.25
-2.90% (-₹2.9)
Prev. close
₹100.15
Volume
0
As of
BSE · may be slightly delayed · 15:32 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About ASSTON PHARMACEUTICALS LIMITED
Asston Pharmaceuticals Limited manufactures pharmaceutical products in India, West Africa, South Africa, and Asian countries. The company provides tablets, such as aceclofenac, albendazole, aminophylline, artemether and lumefantrine, ascorbic acid chewable, azithromycin, b-complex, calcium, cholecalciferol with folic acid, cefixime, cetirizine, ciprofloxacin, co-trimoxazole, cyproheptadine, dexamethasone, diclofenac, ferrous sulphate, folic acid, glucose, griseofulvin, levofloxacin, loperamide HCL, losartan potassium, mebendazole, metformin hydrochloride sustained release, metformin hydrochloride, metronidazole, multivitamin, nitrofurantoin, ofloxacin and ornidazole, pantoprazole, paracetamol, paracetamol, phenylephrine HCL, chlorpheniramine maleate and caffeine, prednisolone, pregabalin SR and methylcobalamin, pyridoxine HCL, rifampicin and isoniazid, rifampicin, isoniazid, pyrazinamide and ethambutol HCL, sildenafil, tadalafil, telmisartan, and zinc sulphate. It also offers capsules, including amoxicillin, ampicillin and cloxacillin, ampicillin, b-complex, cloxacillin, danazol, diclofenac, ibuprofen, paracetamol, caffeine, indomethacin, itraconazole, mecobalamin, alpha lipoic acid, thiamine mononitrate, pyridoxine HCL and folic acid, mefenamic acid, multivitamin, omeprazole, pregabalin, rabeprazole sodium and domperidone SR, rifabutin, and rifampicin; and oral suspension and syrup, which includes albendazole, amodiaquine, antacid, artemether and lumefantrine dry, azithromycin dry, b-complex, cefixime dry, chloroquine, co-trimoxazole, iron, kids cold, kids cough, mebendazole, metronidazole, multivitamin, and paracetamol. In addition, the company provides sachets and oral powder comprising oral rehydration salt, vitamin d3, glucose powder, sorbitol powder, prebiotic and probiotic, and antacids. It sells its products in the form of tablet capsules, syrup, sachet, and injection. The company was incorporated in 2019 and is based in Navi Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Saili Jayaram More
Headquarters
Navi Mumbai
Employees
42
Website
asstonpharmaceuticals.comExchange
View on BSE ↗Key stats
Market cap
₹110.87 Cr
P/E ratio (TTM)
20.6
EPS (TTM)
₹4.92
Beta (1Y · daily vs NIFTY 50)
0.23
Shares float
37.57 L
EPS · quarter ended Mar 2026
₹1.14
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹6.54 Cr | ₹15.59 Cr | ₹25.04 Cr | ₹25.47 Cr | |
| EBITDA | — | ₹2.13 Cr | ₹2.77 Cr | ₹5.86 Cr | ₹5.55 Cr |
| — | ₹1.06 Cr | ₹1.36 Cr | ₹3.85 Cr | ₹3.87 Cr | |
| Diluted EPS | ₹0.13 | ₹1.24 | ₹1.6 | ₹4.53 | ₹4.92 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹13.69 Cr | ₹20.26 Cr | ₹28.12 Cr | ₹51.65 Cr | |
| ₹5.25 Cr | ₹6.82 Cr | ₹7.26 Cr | ₹5.11 Cr | |
| Stockholders' equity | ₹1.99 Cr | ₹6.39 Cr | ₹11.04 Cr | ₹38.86 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹-31.57 L | ₹-3.80 Cr | ₹-2.53 L | ₹-10.18 Cr | |
| Investing cash flow | ₹-91.21 L | ₹-54,000 | ₹73.05 L | ₹-9.91 Cr |
| ₹1.21 Cr | ₹3.69 Cr | ₹-51.25 L | ₹21.18 Cr | |
| Capital expenditure | ₹-25.08 L | ₹-1.03 L | ₹-2.71 L | ₹-10.06 Cr |
| End cash position | ₹12.37 L | ₹64,000 | ₹19.91 L | ₹1.29 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| ASSTON PHARMACEUTICALS LIMITED | ₹111.41 Cr | ₹102 | 20.7 | 2.87 | 9.9% | 0.13 | +1.7% | +4.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Aston Pharmaceuticals: Prakruti R Pali Buys 1.93% Stake
Prakruti R Pali increased her stake in Aston Pharmaceuticals Limited by acquiring an additional 1.93% of equity shares on August 28, 2026. This open market transaction involved 1,64,000 shares. Pali's total holding in the company now stands at 7.26% of the total voting capital.